Arbitration-based non-exclusive license on Glivec eyed

Published: 2002-08-20 06:59:00

Updated: 2002-08-20 06:59:00

The arbitration-based non-exclusive license (ANEL) on Glivec is now emerging as a hot issue, amid the prolonged showdown on its pricing among the interested parties.

According to the Joint Countermeasure Committee of Glivec Settlement and Expanded Publicity of Drugs (JCC), the representatives ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK